9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

 

Archive

Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer

Condition Peritoneal Neoplasms|Retroperitoneal Neoplasms|Gastrointestinal Neoplasms|Adenocarcinoma|Neuroblastoma|Ovarian Neoplasms|Sarcoma|Adrenocortical Carcinoma|Wilms Tumor|Rhabdomyosarcoma|Desmoplastic Small Round Cell Tumor Estimated Enrollment: 10 Age Group: 3 Years to 18 Years   (Child, Adult) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 2005-0917 Study First Received: February 15, 2007 Last Updated: March 29, 2012 Estimated Primary Completion Date: April 2011 Primary Outcome Measures: Maximum Tolerated Dose (MTD) of continuous hyperthermic peritoneal perfusion (CHPP) with cisplatin in children with peritoneal cancer Sponsors and Collaborators: M.D. Anderson Cancer Center Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00436657...

Continue reading

Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2

Condition Non Small Cell Lung Carcinoma Estimated Enrollment: 228 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: H3E-BL-O027-PS2|H3E - US -I023|INCA-Lung001 Study First Received: December 30, 2010 Last Updated: April 18, 2013 Estimated Primary Completion Date: January 2012 Primary Outcome Measures: Overall survival|Safety evaluation|Progression free survival|Response Rate Sponsors and Collaborators: Instituto Nacional de Cancer, Brazil|Eli Lilly and Company Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01836575...

Continue reading

A Study in Non Small Cell Lung Cancer

Condition Non Small Cell Lung Cancer Estimated Enrollment: 63 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 13797|I2I-MC-JMMG Study First Received: June 1, 2010 Last Updated: September 5, 2014 Estimated Primary Completion Date: May 2013 Primary Outcome Measures: Phase 2: Progression Free Survival Time|Phase 1: Recommended Phase 2 Dose of LY2603618|Phase 2: Overall Survival|Phase 2: Overall Tumor Response Rate: Percentage of Participants who Achieved a Confirmed Best Response of Completed Response (CR) or Partial Response (PR)|Phase 2: Change in Tumor Size|Phase 1: Pharmacokinetic: Maximum Concentration (Cmax) (Pemetrexed, Cisplatin and LY2603618)|Phase 1:...

Continue reading

Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors

Condition Cervical Cancer|Fallopian Tube Cancer|Head and Neck Cancer|Lung Cancer|Malignant Mesothelioma|Ovarian Cancer|Pancreatic Cancer|Primary Peritoneal Cavity Cancer Estimated Enrollment: null Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CDR0000316451|NCI-03-C-0243|NCI-6221|NCI-SS1PE-002 Study First Received: August 6, 2003 Last Updated: April 29, 2015 Estimated Primary Completion Date: null Primary Outcome Measures: Sponsors and Collaborators: National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00066651...

Continue reading

Immunotoxin Therapy in Treating Patients With Advanced Cancer

Condition Cervical Cancer|Fallopian Tube Cancer|Head and Neck Cancer|Lung Cancer|Malignant Mesothelioma|Ovarian Cancer|Pancreatic Cancer|Primary Peritoneal Cavity Cancer Estimated Enrollment: null Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CDR0000068351|NCI-01-C-0011|NCI-6249 Study First Received: December 6, 2000 Last Updated: April 29, 2015 Estimated Primary Completion Date: null Primary Outcome Measures: Sponsors and Collaborators: National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00006981...

Continue reading

Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors

Condition Adrenocortical Carcinoma|Brain and Central Nervous System Tumors|Head and Neck Cancer|Liver Cancer|Malignant Mesothelioma|Pheochromocytoma|Sarcoma Estimated Enrollment: 30 Age Group: up to 65 Years   (Child, Adult) Gender: All Study Type: Interventional Study Design Allocation: Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CAN-OTT-9401|CDR0000063892|NCI-V94-0566 Study First Received: November 1, 1999 Last Updated: July 9, 2013 Estimated Primary Completion Date: null Primary Outcome Measures: Sponsors and Collaborators: Ottawa Regional Cancer Centre|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00002608...

Continue reading

Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer

Condition Cancer Estimated Enrollment: 42 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 05-002|12,158 Study First Received: September 16, 2005 Last Updated: January 15, 2016 Estimated Primary Completion Date: October 2013 Primary Outcome Measures: Time-to-progression (TTP)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Overall Survival (OS) Sponsors and Collaborators: University of Pittsburgh|Eli Lilly and Company|Genentech, Inc. Result Received: January 15, 2016 Website Link: https://ClinicalTrials.gov/show/NCT00222729...

Continue reading

A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors

Condition Cancer Estimated Enrollment: 34 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 114746 Study First Received: September 5, 2013 Last Updated: January 16, 2017 Estimated Primary Completion Date: June 2016 Primary Outcome Measures: Part 1: Safety assessment as assessed by adverse events (AEs) and serious adverse events (SAEs)|Part 1: Safety assessment as assessed by 12-lead electrocardiogram (ECG)|Part 1: Safety assessment as assessed by vital signs|Part 1: Safety assessment as assessed by change from baseline in laboratory values|Part 1: Safety assessment as assessed by echocardiogram|Part 1: Safety assessment as assessed...

Continue reading

Thrombin Generation and Platelet Activation in CRS/HIPEC

Condition Mesothelioma; Peritoneum|Pseudomyxoma Peritonei|Peritoneal Carcinomatosis Estimated Enrollment: 27 Age Group: up to 80 Years   (Child, Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Observational Model: Cohort|Time Perspective: Prospective Study ID Numbers: B37120154199 Study First Received: January 12, 2017 Last Updated: January 24, 2017 Estimated Primary Completion Date: July 2016 Primary Outcome Measures: Blood loss|Red blood cell count|White blood cell count|Platelet count|Fibrinogen levels|Prothrombin Time (PT)|Activated Partial Thromboplastin Time (aPTT)|Endogenous Thrombin Potential (Thrombin generation assay (CAT))|Lag Time (Thrombin generation assay (CAT))|Time-to-Thrombin Peak (Thrombin generation assay (CAT))|Thrombin Peak (TP) (Thrombin generation assay (CAT))|P-selectin expression (Platelet activation test (PACT))|αIIbβ3 activation (Platelet activation test (PACT))|A5 EXTEM (Rotational thromboelastometry (ROTEM))|A5 FIBTEM (Rotational thromboelastometry (ROTEM))|A5 HEPTEM...

Continue reading

Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

Condition Lung Cancer|Malignant Mesothelioma|Metastatic Cancer|Thymoma and Thymic Carcinoma Estimated Enrollment: 30 Age Group: Child, Adult, Senior Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CDR0000068889|P30CA016042|UCLA-9908024|NCI-G01-2011 Study First Received: September 13, 2001 Last Updated: October 28, 2015 Estimated Primary Completion Date: December 2006 Primary Outcome Measures: Sponsors and Collaborators: Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00024076...

Continue reading